GLYCAR T cell therapy (Baylor College of Medicine)

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameGLYCAR T cell therapy (Baylor College of Medicine)
Drug Alias NameGPC3-CAR T cellsGPC3-CAR T cell therapyAnti-GPC3 CAR T-cell therapyAnti-glypican-3 CAR T-cell therapyGPC3-CAR transduced T cell therapy +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionGlypican-3 modulatorsInterleukin-15 receptors agonists
TargetsGlypican-3Interleukin-15 receptors
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, HepatocellularEndodermal Sinus Tumor +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsCarcinoma, HepatocellularEndodermal Sinus Tumor +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A